Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.

Anand SinghNathanael PruettShivani DixitSudheer K GaraHaitao WangRoma PahwaDavid S SchrumpChuong D Hoang

Published in: Journal of experimental & clinical cancer research : CR (2023)

We identified an unrecognized molecular vulnerability of DPM based on FACT dependency. CBL0137 alone and in several combinations with different therapeutics showed promising efficacy, including that of improved anti-tumor immunity. Overall, these preclinical findings suggest that CBL0137 could be ideally suited for use in DPM clinical trials.

Keyphrases

clinical trial
transcription factor
climate change
gene expression
dna damage
small molecule
genome wide
cell therapy
phase ii
single molecule
stem cells
open label
mesenchymal stem cells
study protocol
double blind
bone marrow
drug delivery